Medication info

Damet Sustained Release Tablet 10/500 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Bionex Co., Ltd.
Appearance
Pink, bilaterally convex, oval-shaped film-coated tablet
Packaging
30 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202204074 · Approved 2022.11.10

This product's status changed to Approval withdrawn on 2023.10.12. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. This medicine must be swallowed whole and must never be crushed, cut, or chewed. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, with no other symptoms that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum dose of 1000 mg per day. If the eGFR falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months.

Ingredients

Manufacturer
Bionex Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired glycemic control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used in combination with dapagliflozin and metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In particular, for patients with insufficient glycemic control who have cardiovascular diseases or risk factors, reference to expert guidance regarding the impact of dapagliflozin on the occurrence of cardiovascular events should be considered. This medication helps manage blood sugar safely and effectively, providing a positive aid in diabetes treatment.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. This medicine must be swallowed whole and must never be crushed, cut, or chewed. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, with no other symptoms that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum dose of 1000 mg per day. If the eGFR falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months.

Precautions

This medication can very rarely cause a serious condition called lactic acidosis, so it is important to be aware of this symptom. Additionally, caution should be exercised as the risk of hypoglycemia may be increased when used in conjunction with other diabetes medications such as insulin or sulfonylureas. It should not be used in patients with moderate to severe renal impairment or acute renal damage, or it should be used with caution in such cases. In situations where the physical condition is rapidly changing, such as heart disease, dehydration, severe infections, or pre-and post-surgical conditions, it may be necessary to temporarily stop administering this medication. Women who are pregnant or breastfeeding should not take this medication, and women who may become pregnant need to be cautious. This medication may increase the risk of genital and urinary tract infections, so if infection symptoms appear, consult a healthcare provider immediately. Patients at risk for reduced fluid volumes or hypotension should regularly check their blood pressure and fluid status, and may need to discontinue use. It is advisable to avoid alcohol consumption while taking this medication, as excessive drinking can increase the risk of side effects. If blood sugar control fails or abnormal symptoms appear, notify your healthcare provider immediately, and be vigilant about symptoms of hypoglycemia. Elderly patients or patients with impaired renal function should pay particular attention to dosage adjustments and renal monitoring. This medication has not been established as safe and effective in children, so it is not used in this population. When storing the medication, keep it out of reach of children and store it in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • associated genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • fluid volume depletion
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbar pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • reduced renal creatinine clearance
  • dyslipidemia
  • increased blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbance
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular disease
  • tendinosis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The recommended storage temperature is between 1 and 30 degrees Celsius at room temperature. Storing it this way helps maintain the medication's effectiveness and safety.

Appearance and packaging

Appearance

Pink, bilaterally convex, oval-shaped film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.